1. Home
  2. BRN vs LPCN Comparison

BRN vs LPCN Comparison

Compare BRN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barnwell Industries Inc.

BRN

Barnwell Industries Inc.

HOLD

Current Price

$1.07

Market Cap

16.4M

Sector

Energy

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.16

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRN
LPCN
Founded
1956
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.4M
19.1M
IPO Year
1995
2011

Fundamental Metrics

Financial Performance
Metric
BRN
LPCN
Price
$1.07
$2.16
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
97.9K
86.6K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
$13,697,000.00
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$92.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$1.81
52 Week High
$2.28
$12.37

Technical Indicators

Market Signals
Indicator
BRN
LPCN
Relative Strength Index (RSI) 42.97 29.79
Support Level $0.98 $1.81
Resistance Level $1.18 $2.50
Average True Range (ATR) 0.04 0.11
MACD -0.00 0.06
Stochastic Oscillator 28.57 7.58

Price Performance

Historical Comparison
BRN
LPCN

About BRN Barnwell Industries Inc.

Barnwell Industries Inc is an oil and gas company engaged in the acquisition, development, production, and sale of crude oil and natural gas. The Company operates through two segments: the Oil and Natural Gas segment, which focuses on oil and natural gas development, production, acquisitions, and sales in the United States and Canada; and the Land Investment segment, which owns leasehold land interests in Hawaii. The Company generates the majority of its revenue from the Oil and Natural Gas segment. The company operates in two geographic regions, the United States and Canada, with Canada contributing the majority of revenue.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: